Drugs / EAGD T-cell infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03533816 | Jan 2020 → Jan 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | University of Kansas Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EAGD T-cell infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03533816 ↗ |
| Action | Deplete | “ability to recognize malignant cells and kill them” NCT03533816 ↗ |
| Modality | Cell therapy | “gamma delta (γδ) enriched cell therapy product” NCT03533816 ↗ |